<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577107</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002ACN07</org_study_id>
    <nct_id>NCT02577107</nct_id>
  </id_info>
  <brief_title>Head to Head Study of Anti-VEGF Treatment.</brief_title>
  <acronym>RELIANCE</acronym>
  <official_title>An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory single site, open label, randomized, controlled study evaluated plasma
      vascular endothelial growth factor levels after intravitreal injection of ranibizumab
      (Lucentis) and conbercept (Langmu) for neovascular age-related macular degeneration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized, open label study enrolled patients with neovascular AMD who
      were naïve to anti-VEGF therapy or have not received intravitreal anti-VEGF therapy for the
      previous 3 months. Patients were randomized in two treatment arms for 3 months:

        -  Study arm 1: Three monthly injections of 0.5mg Ranibizumab

        -  Study arm 2: Three monthly injections of 0.5mg Conbercept Blood sample (plasma/serum)
           was collected at baseline (pre-dose), 3h post-injections and days 1, 3, 7 and 28,
           following doses 1 and 3 for PK and systemic VEGF analysis. The lab staff was blinded for
           treatment allocation.

      Plasma VEGF concentration was measured by a blinded laboratory using Quantikine® ELISA kits.
      Serum ranibizumab and conbercept concentration will be determined using validated ELISA
      assay.

      The study was divided into 2 stages: the 1st initial feasibility stage with 6 patients per
      arm (12 patients in total) to verify SD for sample size justification and 2nd stage to
      confirm the findings with justified sample size.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2016</start_date>
  <completion_date type="Actual">July 9, 2016</completion_date>
  <primary_completion_date type="Actual">July 9, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day)</measure>
    <time_frame>Baseline, Visit 5 (Day 8 +/- 1 day)</time_frame>
    <description>Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after first injection at Visit 5 (Day 8 +/- 1 day).Blood sample was collected for systemic VEGF. VEGF was measured by a blinded laboratory using ELISA kits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day)</measure>
    <time_frame>Baseline, Visit 10 (Day 67 +/- 1 day)</time_frame>
    <description>Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after third injection at Visit 10 (Day 67 +/- 1 day). Blood sample was collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma VEGF Concentration at Baseline, Visit 2, 3, 4, 5, 6 After 1st Injection</measure>
    <time_frame>Baseline, Visit 2, 3, 4, 5, 6</time_frame>
    <description>Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit Visit 2, 3, 4, 5, 6 after 1st injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma VEGF Concentration at Baseline, Visit 7, 8, 9, 10, 11 After 3rd Injection</measure>
    <time_frame>Baseline, Visit 7, 8, 9, 10, 11</time_frame>
    <description>Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit 7, 8, 9, 10, 11 after 3rd injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three monthly injections of 0.5mg Ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conbercept 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three monthly injections of 0.5mg Conbercept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <arm_group_label>Ranibizumab 0.5 mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conbercept</intervention_name>
    <arm_group_label>Conbercept 0.5 mg</arm_group_label>
    <other_name>Langmu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained before any assessment is performed.

          2. Male or female patient ≥ 50 years of age.

          3. Subfoveal CNV secondary to nAMD.

          4. BCVA score must be between 73 and 24 letters as measured by ETDRS chart

        Exclusion Criteria:

        For both eyes

          1. Any active periocular or ocular infection or inflammation

          2. Uncontrolled glaucoma

          3. Neovascularization of the iris or neovascular glaucoma. For study eye

          4. Choroidal neovascularization of any other cause than wet AMD

          5. Ocular disorders present that may confound interpretation of study results,

          6. Previous treatment with verteporfin PDT (Visudyne®), external-beam radiation therapy,
             focal laser photocoagulation, vitrectomy, submacular surgery, or transpupillary
             thermotherapy.

          7. Structural damage within 0.5 disc diameter of the center of the macula

          8. Atrophy or fibrosis involving the center of the fovea.

          9. Inability of obtaining required lab report. Ocular medical history

         10. History of intravitreal injection with any anti-VEGF drugs within 3 months. Exclusion
             criteria for systemic medical conditions and treatment

         11. Any type of systemic disease or its treatment

         12. Any patients diagnosed with tumor.

         13. Stroke or myocardial infarction less than 3 months.

         14. Known hypersensitivity to indocyanine green, fluorescein, or any component of the
             investigational drug formulation.

         15. Use of any systemic anti-VEGF drugs within 6 months. Exclusion criteria for patient

         16. Patients who have participated in other investigational drug study within 60 days.

         17. Pregnant or nursing (lactating) women.

         18. Inability to comply with study or follow-up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <results_first_submitted>July 9, 2017</results_first_submitted>
  <results_first_submitted_qc>July 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>July 9, 2017</last_update_submitted>
  <last_update_submitted_qc>July 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related macular degeneration,</keyword>
  <keyword>ranibizumab,</keyword>
  <keyword>conbercept,</keyword>
  <keyword>plasma VEGF</keyword>
  <keyword>PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab 0.5 mg</title>
          <description>Three monthly injections of 0.5mg Ranibizumab</description>
        </group>
        <group group_id="P2">
          <title>Conbercept 0.5 mg</title>
          <description>Three monthly injections of 0.5mg Conbercept</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab 0.5 mg</title>
          <description>Three monthly injections of 0.5mg Ranibizumab</description>
        </group>
        <group group_id="B2">
          <title>Conbercept 0.5 mg</title>
          <description>Three monthly injections of 0.5mg Conbercept</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="5.50"/>
                    <measurement group_id="B2" value="69.3" spread="8.41"/>
                    <measurement group_id="B3" value="67.3" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day)</title>
        <description>Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after first injection at Visit 5 (Day 8 +/- 1 day).Blood sample was collected for systemic VEGF. VEGF was measured by a blinded laboratory using ELISA kits.</description>
        <time_frame>Baseline, Visit 5 (Day 8 +/- 1 day)</time_frame>
        <population>Per-protocol Set refers to all subjects who completed the study without any major deviation from the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg</title>
            <description>Three monthly injections of 0.5mg Ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>Conbercept 0.5 mg</title>
            <description>Three monthly injections of 0.5mg Conbercept</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day)</title>
          <description>Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after first injection at Visit 5 (Day 8 +/- 1 day).Blood sample was collected for systemic VEGF. VEGF was measured by a blinded laboratory using ELISA kits.</description>
          <population>Per-protocol Set refers to all subjects who completed the study without any major deviation from the study protocol.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.720" spread="9.5547"/>
                    <measurement group_id="O2" value="-25.833" spread="22.8145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.314</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1613</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.618</ci_lower_limit>
            <ci_upper_limit>31.011</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day)</title>
        <description>Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after third injection at Visit 10 (Day 67 +/- 1 day). Blood sample was collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits.</description>
        <time_frame>Baseline, Visit 10 (Day 67 +/- 1 day)</time_frame>
        <population>Per-protocol Set refers to all subjects who completed the study without any major deviation from the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg</title>
            <description>Three monthly injections of 0.5mg Ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>Conbercept 0.5 mg</title>
            <description>Three monthly injections of 0.5mg Conbercept</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day)</title>
          <description>Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after third injection at Visit 10 (Day 67 +/- 1 day). Blood sample was collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits.</description>
          <population>Per-protocol Set refers to all subjects who completed the study without any major deviation from the study protocol.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.100" spread="17.4799"/>
                    <measurement group_id="O2" value="-22.220" spread="12.9239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma VEGF Concentration at Baseline, Visit 2, 3, 4, 5, 6 After 1st Injection</title>
        <description>Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit Visit 2, 3, 4, 5, 6 after 1st injection</description>
        <time_frame>Baseline, Visit 2, 3, 4, 5, 6</time_frame>
        <population>Per-protocol Set refers to all subjects who completed the study without any major deviation from the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg</title>
            <description>Three monthly injections of 0.5mg Ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>Conbercept 0.5 mg</title>
            <description>Three monthly injections of 0.5mg Conbercept</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma VEGF Concentration at Baseline, Visit 2, 3, 4, 5, 6 After 1st Injection</title>
          <description>Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit Visit 2, 3, 4, 5, 6 after 1st injection</description>
          <population>Per-protocol Set refers to all subjects who completed the study without any major deviation from the study protocol.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.400" spread="6.3816"/>
                    <measurement group_id="O2" value="42.200" spread="23.4269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.958" spread="19.9813"/>
                    <measurement group_id="O2" value="14.920" spread="12.4920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 (Day 2 +/- 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.517" spread="19.2783"/>
                    <measurement group_id="O2" value="24.590" spread="39.2435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 (Day 4 +/- 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.150" spread="5.5587"/>
                    <measurement group_id="O2" value="7.213" spread="4.9250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 (Day 8 +/- 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.000" spread="4.7979"/>
                    <measurement group_id="O2" value="19.075" spread="4.5051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6 (Day 30 +/- 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.092" spread="13.2356"/>
                    <measurement group_id="O2" value="25.270" spread="15.0967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma VEGF Concentration at Baseline, Visit 7, 8, 9, 10, 11 After 3rd Injection</title>
        <description>Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit 7, 8, 9, 10, 11 after 3rd injection</description>
        <time_frame>Baseline, Visit 7, 8, 9, 10, 11</time_frame>
        <population>Per-protocol Set refers to all subjects who completed the study without any major deviation from the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5 mg</title>
            <description>Three monthly injections of 0.5mg Ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>Conbercept 0.5 mg</title>
            <description>Three monthly injections of 0.5mg Conbercept</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma VEGF Concentration at Baseline, Visit 7, 8, 9, 10, 11 After 3rd Injection</title>
          <description>Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit 7, 8, 9, 10, 11 after 3rd injection</description>
          <population>Per-protocol Set refers to all subjects who completed the study without any major deviation from the study protocol.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.250" spread="11.8610"/>
                    <measurement group_id="O2" value="36.520" spread="19.2278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (Day 60 +/- 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.383" spread="12.7727"/>
                    <measurement group_id="O2" value="5.720" spread="2.1690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8 (Day 61 +/- 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.533" spread="48.1293"/>
                    <measurement group_id="O2" value="6.820" spread="4.6287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9 (Day 63 +/- 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.067" spread="40.2585"/>
                    <measurement group_id="O2" value="8.070" spread="4.6452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10 (Day 67 +/- 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.150" spread="25.4399"/>
                    <measurement group_id="O2" value="14.300" spread="9.6690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11 (Day 90 +/- 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.067" spread="18.0828"/>
                    <measurement group_id="O2" value="56.020" spread="27.0819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab 0.5 mg</title>
          <description>Three monthly injections of 0.5mg Ranibizumab</description>
        </group>
        <group group_id="E2">
          <title>Conbercept 0.5 mg</title>
          <description>Three monthly injections of 0.5mg Conbercept</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fracture of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fracture of rib</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thoracic injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

